ArticleMethodsX2025
Preparation and validation of nanomolar aqueous bilirubin standard solutions.
Article in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Indirect bilirubin mitigates tubular vacuolization and injury in experimental contrast nephropathy.BMC nephrology · 2026Article
- Fluorometric Nanoscale Analysis of Bilirubin and Biliverdin in Human Cerebrospinal Fluid.ACS chemical neuroscience · 2025Article
- The HELP-UnaG Fusion Protein as a Bilirubin Biosensor: From Theory to Mature Technological Development.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilirubin (BR) is the product of cellular heme catabolism and the main bile pigment in animal blood. It is an established biomarker for hemolysis and liver function. Over the last decade, mild hyperbilirubinemia has been shown to be a biomarker for a lower risk of cardiovascular disease, due to its antioxidant and anti-inflammatory effects. In order to use bilirubin as a predictive biomarker, new powerful methods for its direct analysis in human blood are currently being developed. To harmonize the different methods, it is essential to use high-quality BR standard solutions for assay calibration. We present here a protocol for the preparation of stable standard solutions in the range of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.